MRD negativity rates following carfilzomib, dex & dara in R/R myeloma

MRD negativity rates following carfilzomib, dex & dara in R/R myelomaПодробнее

2019 Multiple Myeloma Symposium | Novel and Next Generation TherapyПодробнее

MRD-negativity rates in the IKEMA trial of isa plus kD in R/R myelomaПодробнее

Daratumumab, Carfilzomib, Lenalidomide & Dexamethasone w/ MRD Res. Adapted Therapy in Newly Diag. MMПодробнее

Promising MRD negativity rates achieved in a trial of weekly KRd-D in myelomaПодробнее

How do MRD negativity rates with Dara-KRd compare to other treatment options in patients with NDMM?Подробнее

Real-world use of carfilzomib for R/R myeloma patientsПодробнее

Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in...Подробнее

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in ...Подробнее

Reducing SMM transformation risk: carfilzomib, lenalidomide & dexamethasoneПодробнее

MRD assessment in R/R myeloma treated with VenKdПодробнее

Daratumumab, Carfilzomib, Lenalidomide and Dex for HR Smoldering Multiple Myeloma: ASCENT TrialПодробнее

Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma ptsПодробнее

Daratumumab reduces carfilzomib-related cardiac toxicities in R/R myelomaПодробнее

MASTER trial: Dara-KRD, ASCT & MRD-directed therapy in myelomaПодробнее

The immune microenvironment predicts sustained MRD-negativity after D-KRd treatment for myelomaПодробнее

DARIA: daratumumab with ixazomib and dexamethasone for R/R myelomaПодробнее

Post Hoc Analysis of Sustained MRD Negativity (GRIFFIN Trial) in TE NDMM PatientsПодробнее

MANHATTAN: carfilzomib, lenalidomide, dexamethasone, and daratumumab for newly diagnosed myelomaПодробнее

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myelomaПодробнее